Evidence map›Paper›PMID 27943107›Full record

ArticleDiabetes therapy : research, treatment and education of diabetes and related disorders2017

The Efficacy of IDegLira (Insulin Degludec/Liraglutide Combination) in Adults with Type 2 Diabetes Inadequately Controlled with a GLP-1 Receptor Agonist and Oral Therapy: DUAL III Randomized Clinical Trial.

Sultan Linjawi, Bruce W Bode, Louis B Chaykin, Jean-Pierre Courrèges, Yehuda Handelsman, Lucine M Lehmann, Abhishek Mishra, Richard W Simpson

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetes therapy : research, treatment and education of diabetes and related disorders, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT01676116. Cited by 84 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
84citing papers in PubMed, 8 pooled it
11.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01676116 phase3completed

The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and OAD Therapy (DUAL™ III -GLP-1 Switch)

Ran2012Enrolled438Registered outcomes9Posted comparisons1ConditionsDiabetes, Diabetes Mellitus, Type 2Armsexenatide, insulin degludec/liraglutide, liraglutide
PMID 30383495other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

84 citing papers in PubMed, 8 syntheses or guidelines pooled it, 133 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Guideline
  4. Pooled it
  5. Guideline
  6. Pooled it
  7. Guideline
  8. Pooled it
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

24 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 8 institutions in 5 countries.

Sultan LinjawiCoffs Endocrine & Diabetes Services, Coffs Harbour, NSW, Australia. coffsendo@gmail.com.
Bruce W BodeAtlanta Diabetes Associates, Atlanta, GA, USA.
Louis B ChaykinMeridien Research, Bradenton, FL, USA.
Jean-Pierre CourrègesDiabetology and Vascular Disease Unit, General Hospital, Narbonne, France.
Yehuda HandelsmanMetabolic Institute of America, Tarzana, CA, USA.
Lucine M LehmannNovo Nordisk A/S, Søborg, Denmark.
Abhishek MishraNovo Nordisk, Bangalore, India.
Richard W SimpsonMonash University and Eastern Health, Box Hill, VIC, Australia.
Atlanta Diabetes Associates · USCoffs Harbour City Council · AUEastern Health · AULaboratoire de Biotechnologie de l'Environnement · FRMeridien Research · USNovo Nordisk (Denmark) · DKNovo Nordisk (India) · INTarzana Treatment Centers · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe progressive nature of type 2 diabetes necessitates treatment intensification. This often involves intensification with oral antidiabetic drugs (OADs) initially, followed by other agents, such as glucagon-like peptide-1 receptor agonists (GLP-1RAs), with the majority of patients eventually requiring insulin therapy. Therefore, this trial aimed to investigate the efficacy of IDegLira (combination of insulin degludec and liraglutide) in controlling glycemia in adults with type 2 diabetes who were inadequately controlled on a GLP-1RA and OADs.

methodsIn this 26-week open-label phase 3b trial, patients on maximum-dose GLP-1RA therapy (liraglutide once daily or exenatide twice daily) with metformin alone or with pioglitazone and/or sulfonylurea were randomized 2:1 to IDegLira once daily (n = 292) or to unchanged GLP-1RA therapy (n = 146), continuing OADs at the pre-trial dose.

resultsAfter 26 weeks, HbA

conclusionsIDegLira provided superior glycemic control versus unchanged GLP-1RA and represents an efficacious intensification approach in patients inadequately controlled on GLP-1RAs.

trial registrationClinicalTrials.gov #NCT01676116.

fundingNovo Nordisk.

Indexed as

Clinical trialGLP-1 receptor agonistIDegLiraInsulin therapyType 2 diabetes

Identifiers

PMID27943107
PMCPMC5306117
OpenAlexW2559748650

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.